Short Interest in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Increases By 8.1%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 35,950,000 shares, an increase of 8.1% from the January 15th total of 33,260,000 shares. Based on an average trading volume of 3,120,000 shares, the short-interest ratio is currently 11.5 days. Approximately 14.5% of the shares of the stock are sold short.

Shares of FOLD traded up $0.01 during midday trading on Friday, hitting $10.98. The company’s stock had a trading volume of 2,114,468 shares, compared to its average volume of 3,157,472. Amicus Therapeutics has a one year low of $7.11 and a one year high of $14.61. The company’s fifty day simple moving average is $9.73 and its two-hundred day simple moving average is $9.61. The company has a quick ratio of 6.10, a current ratio of 6.20 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -6.99 and a beta of 1.54.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The company had revenue of $48.80 million for the quarter, compared to analyst estimates of $48.05 million. During the same quarter last year, the company posted ($0.84) EPS. The company’s revenue for the quarter was up 136.9% compared to the same quarter last year. On average, research analysts predict that Amicus Therapeutics will post -1.25 earnings per share for the current year.

A number of research firms have commented on FOLD. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, January 9th. Robert W. Baird reiterated a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research note on Thursday, January 9th. Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research note on Monday, November 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target (up previously from $19.00) on shares of Amicus Therapeutics in a research note on Tuesday, February 4th. Eight analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $19.03.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.38, for a total transaction of $207,600.00. Following the transaction, the chief executive officer now owns 755,694 shares in the company, valued at approximately $7,844,103.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jay Barth sold 9,753 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $9.55, for a total value of $93,141.15. Following the transaction, the insider now owns 137,674 shares in the company, valued at approximately $1,314,786.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 310,637 shares of company stock worth $3,103,288. Corporate insiders own 2.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC increased its stake in shares of Amicus Therapeutics by 2.1% in the 4th quarter. Perceptive Advisors LLC now owns 25,132,364 shares of the biopharmaceutical company’s stock valued at $244,789,000 after purchasing an additional 522,664 shares during the last quarter. BlackRock Inc. increased its stake in shares of Amicus Therapeutics by 10.8% in the 2nd quarter. BlackRock Inc. now owns 18,580,413 shares of the biopharmaceutical company’s stock valued at $231,885,000 after purchasing an additional 1,805,661 shares during the last quarter. State Street Corp boosted its holdings in shares of Amicus Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 11,581,181 shares of the biopharmaceutical company’s stock valued at $92,881,000 after acquiring an additional 1,783,202 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Amicus Therapeutics by 10.9% during the 4th quarter. Victory Capital Management Inc. now owns 4,066,839 shares of the biopharmaceutical company’s stock valued at $35,951,000 after acquiring an additional 398,955 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Amicus Therapeutics by 42.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,372,952 shares of the biopharmaceutical company’s stock valued at $32,852,000 after acquiring an additional 1,007,617 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: What are different types of coverage ratios?

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.